.png "back to home page")
Not only is the CureVac vaccine late to the game, but preliminary data shows it is only 47 percent effective in preventing COVID-19.
— POLITICOEurope (@POLITICOEurope) June 18, 2021
https://t.co/N05fIwRbZ8
mRNAワクチンだからといって「ぱねぇ」とは限らず独CureVac社製ワクチンの2回接種後の有効率は47%。原因はModernaとBioNtech/Pfizerはプソイドウリジンを組み込んだ修飾RNAを使用してるのに対しCureVacはウリジンを使用したためだろうとのこと。 https://t.co/S8dpZtY7UD https://t.co/YhV923qlcp
— Spica (@Kelangdbn) June 19, 2021
CureVac COVID vaccine let-down spotlights mRNA design challenges
— Robert W Malone, MD (@RWMaloneMD) June 18, 2021
Nature
(I agree, the problem is the dose was too low, far lower than Pfizer or Moderna)https://t.co/EUHgucA32B
Costly Mistake
— Dr Able Lawrence?MD DM (@abledoc) June 19, 2021
In the vaccine battle between pseudouridine modified & unmodified RNA, round one goes to modified RNA
Failure of CureVacs mRNA vaccine using unmodified RNA (dose limited by toxicity is a major setback for the company. #CovidVaccine https://t.co/abu3knUfc5
“Modified mRNA has won this game.” What CureVac's beleaguered trial results mean for mRNA vaccine designs:https://t.co/uADsYsSorT
— Elie Dolgin (@ElieDolgin) June 18, 2021
@NatureNews @kkariko @PhilipJSantang1 @Nanimal247 @rein_verbeke @jfkirkegaard
CureVac COVID vaccine let-down spotlights mRNA design challenges - via @Nature https://t.co/pJ1yU98eXr
— Mike Mitchell (@MJMitchell_Lab) June 19, 2021
第３のmRNAワクチン、期待はずれ。ドイツのCureVacは、6月16日に40,000人の試験からの予備データが残念な結果に終わったと発表した。先行の２つのmRNAワクチンとは違い冷蔵保存が可能などの利点があったが、その修飾されていない塩基のせいで、投与量を上げられなかったからかhttps://t.co/OgFkGsO6ZO
— サイエンスあれこれ (@sarekore) June 19, 2021
CureVac blamed the poor performance of its mRNA vaccine on virus variants. But the vaccine itself may be the problem, @sciencecohen reports. https://t.co/ODY4ERSboH
— Martin Enserink (@martinenserink) June 18, 2021
こちらの記事の方が詳しいかもhttps://t.co/BJAvk8dOCK
— サイエンスあれこれ (@sarekore) June 19, 2021
Lots of theories about why CureVac's mRNA vaccine performed so poorly. Could it be that it was too natural?https://t.co/zdyudasMiK pic.twitter.com/aqmB8CjcBc
— Jon Cohen (@sciencecohen) June 18, 2021
CureVac COVID vaccine let-down identifies mRNA design challenges - important lessons to guide the future design of mRNA vaccines against COVID-19 & other diseases #vaccine https://t.co/7Z4vKxZfo5
— Magdalena Skipper (@Magda_Skipper) June 20, 2021